Keep in mind, AEGR skyrocketed from $25 to $75 based on the approval of ONE drug in a limited patient population
ISIS has a MASSIVE PIPELINE of drugs and now a proven technology with the latest trial. The stock will not need FDA approval to have a similar rally as AEGR did because the market is forward looking and investors will anticipate future FDA approval based on excellent trial results.
This could be the most promising biotech investment in the market, especially with late stage pipeline and plenty of news due out within the next two months.
AEGR has a float of 24 million shares -while isis has a float of 102million shares-so at this point -isis is at 104 dollars a share id there were only 24 million shares-2x the price of aegr
102mill times 26.50-isis=2.6billion
24 mil x 63-aegr=1.5billion